Diagnostics group Tepnel raises funds for new Scottish facility

Published: 2-Jun-2006

Tepnel Life Sciences, a UK-based international molecular diagnostics and research products supplier, has successfully raised


Tepnel Life Sciences, a UK-based international molecular diagnostics and research products supplier, has successfully raised £1.2m by placing new shares. The funds will be used for the completion of the company's new build 18,000ft2 facility in Livingston, Scotland and will also provide additional working capital as required by an increase in sales.

The new facility will enable the company to consolidate its operations in Edinburgh and Glasgow and will incorporate pharmaceutical services including high throughput genotyping and protein analysis.

Ben Matzilevich, ceo said: "We are executing against our strategic plan. We continue to improve our results while increasing our market share with major UK pharmaceutical companies. This facility in Scotland is an essential component of the long term strategy and should also allow us to offer gene analysis, sequencing and proteomics."

Tepnel provides molecular diagnostics and research products and services including DNA purification kits and reagents, scientific services for nucleic acid purification, drug analysis, genotyping and genetically modified foods.

In March 2006, the group completed the £30,000 acquisition of the GenXTrak DNA extraction business from UK-based Whatman plc. The Cambridge based GenXTrak business will now operate within Tepnel's service division, offering rapid extraction, purification, quantification and normalisation of clinical DNA samples.

You may also like